Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
GlobeNewswire
*If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately..
